Tulsa's adult obesity and uninsured rates, the dose-tier pricing pattern in the local cash market, the city's thirteen-year primary-care shortage designation, and SoonerCare's exclusion, every figure sourced.
38.8% of adults inside Tulsa city limits have obesity in the CDC's PLACES place-level estimates (2024 release, 2022 survey data) 1, against 36.8% for Oklahoma as a whole in the CDC's 2024 BRFSS estimates 2. Those come from different survey years, so read the gap as a direction rather than a decimal. What is measured on the same footing is coverage: 15.3% of Tulsa residents are uninsured in the 2024 ACS one-year estimates 5, and median household income is $60,930 6.
SoonerCare covers no GLP-1 medication for obesity or weight loss 8. For a large share of the city, then, the cash price is the entire question, and Tulsa's cash market has a specific pattern worth understanding before you buy.
Slim Care, with locations in downtown Tulsa and Owasso, posts its semaglutide pricing by dose: $50 per week at 0.25 to 0.5 mg, $100 per week at 0.6 to 1.0 mg, and $120 per week at 1.1 to 2.4 mg, with in-person physician visits included and a free consultation required first 10. Those are the clinic's own published tiers, and they are transparent, which is more than most of this market offers.
Do the arithmetic the ladder implies. At about 4.3 weeks per month, $50 per week is roughly $215 a month, and that is the number the advertising leads with. But 0.25 mg is a starting dose, not a treatment dose: standard titration moves most people upward over the first few months, and the therapeutic range sits in the top tier. At $100 to $120 per week, the same program runs roughly $430 to $520 a month. The teaser price is real. It just is not where treatment lives.
Nothing about that is deceptive on the clinic's part; the tiers are published, and pricing by dose reflects the fact that a higher dose uses more drug. The problem is what it does to a household budget in a city where the median income is $60,930 6 and 15.3% of residents have no coverage to fall back on 5. You commit at one number and re-decide at another, usually around month three or four, which is also the point at which stopping costs you the progress you have made.
Vital Life in Tulsa shows the same dose-linked shape in different packaging: semaglutide advertised starting at $250.00 for the first eight-to-twelve-week supply with a stated maximum of $360.00 per month, and tirzepatide from a $290 six-week starter supply, rising to $427 for the 5 mg six-week supply 11. In both cases the price is attached to the dose, so the cost of treatment rises exactly as the clinical plan is working.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
The part that matters most in this particular market is the second half of that sentence: the price is also the same at every dose. Moving from 0.25 mg to 2.4 mg does not change your bill, because the plan is priced monthly rather than per milligram. There is no tier you graduate into and no repricing conversation partway through titration.
HRSA's shortage-area file shows the LI-Tulsa County low-income primary-care designation first made in January 2013 and still active, covering 223,729 people at a population-to-provider ratio of 5,229 to 1 7. That is the longest-running shortage designation of any city we have written about. Designations elsewhere in our coverage are months old; Tulsa's is thirteen years old, which describes a structural condition rather than a temporary staffing dip.
It would be wrong to say Tulsa lacks specialists. OU Health Physicians operates a Metabolic & Bariatric Surgery Clinic in the city 9, which is genuine academic-affiliated obesity care, in-city, not a suburban satellite. The shortage numbers describe a different group: the low-income population inside the designated area, for whom a specialist referral pathway and a $430-a-month cash teaser program are equally out of reach. A city can hold both facts at once, and Tulsa does.
For that group the practical barrier is usually the front door: finding a primary-care provider with capacity, then affording whatever comes next. Telehealth answers the first half directly. With Astra, a licensed provider reviews your intake usually within 24 hours, medication ships overnight in discreet packaging, there are no clinic visits, you can message your care team at any point in treatment, and you are only charged if a provider prescribes.
SoonerCare, Oklahoma's Medicaid program, does not cover GLP-1 medications for obesity or weight loss. Coverage exists for diabetes indications and requires prior authorization 8. If obesity is your only indication, the pharmacy benefit is not a path, and that exclusion is a large part of why Tulsa's cash-pay market looks the way it does.
Commercial coverage varies plan by plan. Some Oklahoma employer plans cover Wegovy or Zepbound with prior authorization, others exclude the entire weight-loss category, and some require documented participation in a lifestyle program first. Check your own formulary and its prior-authorization criteria before paying cash: a covered brand product with a workable copay beats any cash price, and it costs nothing to look. Oklahoma's telehealth statute and its compounding rules are set out in full on the Oklahoma GLP-1 hub.
Astra's provider group and partner pharmacies are licensed to serve patients in Oklahoma, Tulsa and the rest of Green Country included. Prescribing rules, compounding rules, and the statutory citations behind them are on the Oklahoma GLP-1 hub.
Astra treats patients in Oklahoma through state-licensed physicians.
Several Tulsa clinics price by dose rather than by month. Slim Care, for example, posts $50 per week at 0.25 to 0.5 mg, $100 per week at 0.6 to 1.0 mg, and $120 per week at 1.1 to 2.4 mg. Because standard titration moves most patients up over the first few months, the price you start at is rarely the price you stay at: the top tier works out to roughly $430 to $520 a month. Astra prices by month instead, so compounded semaglutide is $68 per month on the 12-month plan at every dose, and a dose increase never changes the bill.
On the posted figures, yes, and the gap widens as your dose rises. At therapeutic doses the local tiers we checked in August 2026 work out to roughly $430 to $520 per month, with one clinic stating a $360 per month maximum. Astra's compounded semaglutide is $68 per month on the 12-month plan. That is a national price rather than a Tulsa deal: the same figure applies in Oklahoma City, in Dayton, and everywhere else we operate.
Not for obesity or weight loss. SoonerCare covers GLP-1 medications only for diabetes indications, and those require prior authorization. Commercial plans vary, so check your formulary. Full state coverage and prescribing detail is on our Oklahoma GLP-1 hub at /glp-1/oklahoma/.
In defined circumstances, yes. Compounded semaglutide is dispensed by state-licensed US compounding pharmacies under a patient-specific prescription and is not an FDA-approved product; since FDA declared the semaglutide shortage resolved in February 2025, compounding is limited to narrow 503A situations such as a documented clinical need the approved product cannot meet. Whether that applies to you is a clinical determination a licensed provider makes. The verified state detail is on our Oklahoma GLP-1 hub at /glp-1/oklahoma/.
No. Under 59 O.S. Section 478.1, an Oklahoma-licensed physician may establish a valid physician-patient relationship by telemedicine with no prior in-person visit for non-controlled medications such as semaglutide and tirzepatide. The full statutory detail is in the telehealth section of our Oklahoma GLP-1 hub at /glp-1/oklahoma/.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.